Search

Your search keyword '"Finn, Matthew T."' showing total 147 results
Start Over Author "Finn, Matthew T."
147 results on '"Finn, Matthew T."'

3. Association of Modified Body Mass Index With In-Hospital Outcomes After Intermediate or High-Risk Pulmonary Embolism

Author

Saleem, Danial, Madhavan, Mahesh V., Nigoghossian, Caroline Der, Driggin, Elissa, Nouri, Shayan N., Burton, John, Zilinyi, Robert, Snyder, Daniel J., Lumish, Heidi, Lavelle, Michael, Li, Jianhua, Rosenzweig, Erika B., Takeda, Koji, Kirtane, Ajay J., Fried, Justin, Brodie, Daniel, Agerstrand, Cara, Einstein, Andrew J., Maurer, Mathew, Parikh, Sahil A., Sethi, Sanjum S., and Finn, Matthew T.

Published
2023
Full Text
View/download PDF

4. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research

Author

Généreux, Philippe, Piazza, Nicolo, Alu, Maria C., Nazif, Tamim, Hahn, Rebecca T., Pibarot, Philippe, Bax, Jeroen J., Leipsic, Jonathon A., Blanke, Philipp, Blackstone, Eugene H., Finn, Matthew T., Kapadia, Samir, Linke, Axel, Mack, Michael J., Makkar, Raj, Mehran, Roxana, Popma, Jeffrey J., Reardon, Michael, Rodes-Cabau, Josep, Van Mieghem, Nicolas M., Webb, John G., Cohen, David J., and Leon, Martin B.

Published
2021
Full Text
View/download PDF

6. Synthesis and characterization of a high-temperature polycyanophosphate resin.

Author

Dysart, Jennifer L., Chaloux, Brian L., Finn, Matthew T., Hendrix, Justin W., Laskoski, Matthew, and Epshteyn, Albert

Subjects
SILVER nitrate, POLYMERS, NUCLEAR magnetic resonance spectroscopy, MOIETIES (Chemistry)
Abstract

A phosphorus-containing polymer with very high thermo-oxidative stability was synthesized for the first time by addition of silver nitrate to tricyanophosphine (P(CN)3). By optimizing the reaction time and silver nitrate concentration to a 1:1 molar ratio, a new polycyanophosphate [p(CP)] was formed as the primary phosphorus-containing product over the competing species, P(CN)3. The reactions and products were monitored by FT-IR, ICP-OES, NMR, and XPS spectroscopic techniques, which indicated a complicated oxidation reaction that converted the P(III) precursor species to P(V) polyphosphate species with pendant cyano- and isocyano- moieties. The p(CP) resin was found to contain a high (17.6 at.%) amount of phosphorus by ICP-OES, which contributed to its excellent thermo-oxidative resistance with a high char yield of over 60 wt.% at 1000 °C (1273 K) in air, indicating that the material could be particularly useful for high-temperature applications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Intravascular Ultrasound Analysis of Intraplaque Versus Subintimal Tracking in Percutaneous Intervention for Coronary Chronic Total Occlusions and Association With Procedural Outcomes

Author

Song, Lei, Maehara, Akiko, Finn, Matthew T., Kalra, Sanjog, Moses, Jeffrey W., Parikh, Manish A., Kirtane, Ajay J., Collins, Michael B., Nazif, Tamim M., Fall, Khady N., Hatem, Raja, Liao, Ming, Kim, Tiffany, Green, Philip, Ali, Ziad A., Batres, Candido, Leon, Martin B., Mintz, Gary S., and Karmpaliotis, Dimitri

Published
2017
Full Text
View/download PDF

10. Abstract 17258: The Relationship Between D-Dimer Levels and Deep Venous Thrombosis in COVID-19: An Analysis From a Quaternary Academic Medical Center in New York City

Author

Madhavan, Mahesh V, Gupta, Aakriti, Bikdeli, Behnood, Redfors, Björn, Hennessey, Jessica, Lawlor, Matthew, Poterucha, Timothy J, Nalbandian, Ani, Driggin, Elissa, Elias, Pierre, Ranard, Lauren S, Nabavi Nouri, Shayan, Jianhua, Li, Finn, Matthew T, Ingrassia, Joseph, Eisenberger, Andrew, Masoumi, Amirali, Uriel, Nir, Leon, Martin B, Kirtane, Ajay J, Parikh, Sahil, and Sethi, Sanjum

Published
2020
Full Text
View/download PDF

11. SEX DIFFERENCES IN PRESENTATION, MANAGEMENT AND OUTCOMES OF ACUTE PULMONARY EMBOLISM

Author

Alsaloum, Marissa, primary, Zilinyi, Robert, additional, Snyder, Daniel, additional, Madhavan, Mahesh, additional, Saleem, Danial, additional, Rosenzweig, Erika, additional, Takeda, Koji, additional, Brodie, Daniel, additional, Eisenberger, Andrew, additional, Agerstrand, Cara, additional, Finn, Matthew T., additional, Kirtane, Ajay J., additional, Parikh, Sahil A., additional, and Sethi, Sanjum S., additional

Published
2023
Full Text
View/download PDF

14. The “Lollipop” During Catheter-Directed Thrombectomy

Author

Concha, Daniella, primary, Sethi, Sanjum S., additional, Sharma, Navneet, additional, Takeda, Koji, additional, Pucillo, Anthony, additional, Leon, Martin B., additional, Berman-Rosenzweig, Erika, additional, Kirtane, Ajay J., additional, Parikh, Sahil A., additional, and Finn, Matthew T., additional

Published
2022
Full Text
View/download PDF

23. Electronic Effects of Support Doping on Hydrotalcite-Supported Iridium N-Heterocyclic Carbene Complexes

Author

Wang, Kai, Horlyck, Jonathan, Finn, Matthew T., Mesa, Marta Granollers, Voutchkova-Kostal, Adelina, Wang, Kai, Horlyck, Jonathan, Finn, Matthew T., Mesa, Marta Granollers, and Voutchkova-Kostal, Adelina

Abstract

The electronic effects of supports on immobilized organometallic complexes impact their activity and lifetime, yet remain poorly understood. Here we describe a systematic study of the support effects experienced by an organometallic complex immobilized on doped hydrotalcite-like materials. To that end, we describe the synthesis and characterization of the first organometallic species immobilized on a palette of doped hydrotalcites via sulfonate linkers. The organometallic species consists of iridium N-heterocyclic carbene (NHC) carbonyl complex ([Na][Ir-(NHC-Ph-SO3)2(CO)2]), a highly active molecular catalyst for transfer hydrogenation of glycerol. The hydrotalcite supports are composed of Al, Mg, and a compatible transition-metal dopant (Fe, Cu, Ni, Zn). The materials were characterized extensively by STEM, XPS, TGA, PXRD, FT-IR, N2 desorption, ICP-AES, TPD, and microcalorimetry to probe the morphology and electronic properties of the support and elucidate structure–property relationships.

Published
2022

24. MULTI-VESSEL PCI AND CABG DEMONSTRATE SIGNIFICANT IMPROVEMENTS IN POST-PROCEDURE GLOBAL LONGITUDINAL STRAIN AND LEFT VENTRICULAR EJECTION FRACTION

Author

Jain, Rashmi, primary, Finn, Matthew T., additional, Hamid, Nadira, additional, Hahn, Rebecca T., additional, Wessler, Jeffrey, additional, Lebehn, Mark, additional, Hyun, Lee Jin, additional, Prasad, Megha, additional, Masoumi, Amirali, additional, Ahmad, Yousif, additional, Leon, Martin B., additional, Karmpaliotis, Dimitrios I., additional, Kirtane, Ajay J., additional, and Moses, Jeffrey W., additional

Published
2022
Full Text
View/download PDF

26. Combined Spectroscopic and Computational Investigation on the Oxidation of exo-Tetrahydrodicyclopentadiene (JP-10; C10H16) Doped with Titanium–Aluminum–Boron Reactive Metal Nanopowder

Author

Brotton, Stephen J., primary, Perera, Sahan D., additional, Misra, Anupam, additional, Kleimeier, N. Fabian, additional, Turner, Andrew M., additional, Kaiser, Ralf I., additional, Palenik, Mark, additional, Finn, Matthew T., additional, Epshteyn, Albert, additional, Sun, Bing-Jian, additional, Zhang, Li-Jie, additional, and Chang, Agnes H. H., additional

Published
2021
Full Text
View/download PDF

29. Valve Academic Research Consortium 3:Updated endpoint definitions for aortic valve clinical research

Author

Généreux, Philippe, Piazza, Nicolo, Alu, Maria C., Nazif, Tamim, Hahn, Rebecca T., Pibarot, Philippe, Bax, Jeroen J., Leipsic, Jonathon A., Blanke, Philipp, Blackstone, Eugene H., Finn, Matthew T., Kapadia, Samir, Linke, Axel, Mack, Michael J., Makkar, Raj, Mehran, Roxana, Popma, Jeffrey J., Reardon, Michael, Rodes-Cabau, Josep, Van Mieghem, Nicolas M., Webb, John G., Cohen, David J., Leon, Martin B., Généreux, Philippe, Piazza, Nicolo, Alu, Maria C., Nazif, Tamim, Hahn, Rebecca T., Pibarot, Philippe, Bax, Jeroen J., Leipsic, Jonathon A., Blanke, Philipp, Blackstone, Eugene H., Finn, Matthew T., Kapadia, Samir, Linke, Axel, Mack, Michael J., Makkar, Raj, Mehran, Roxana, Popma, Jeffrey J., Reardon, Michael, Rodes-Cabau, Josep, Van Mieghem, Nicolas M., Webb, John G., Cohen, David J., and Leon, Martin B.

Abstract

Aims: The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these endpoints for transcatheter and surgical aortic valve clinical trials. Rapid evolution of the field, including the emergence of new complications, expanding clinical indications, and novel therapy strategies have mandated further refinement and expansion of these definitions to ensure clinical relevance. This document provides an update of the most appropriate clinical endpoint definitions to be used in the conduct of transcatheter and surgical aortic valve clinical research. Methods and results: Several years after the publication of the VARC-2 manuscript, an in-person meeting was held involving over 50 independent clinical experts representing several professional societies, academic research organizations, the US Food and Drug Administration (FDA), and industry representatives to (i) evaluate utilization of VARC endpoint definitions in clinical research, (ii) discuss the scope of this focused update, and (iii) review and revise specific clinical endpoint definitions. A writing committee of independent experts was convened and subsequently met to further address outstanding issues. There were ongoing discussions with FDA and many experts to develop a new classification schema for bioprosthetic valve dysfunction and failure. Overall, this multi-disciplinary process has resulted in important recommendations for data reporting, clinical research methods, and updated endpoint definitions. New definitions or modifications of existing definitions are being proposed for repeat hospitalizations, access site-related complications, bleeding events, conduction disturbances, cardiac structural complications, and bioprosthetic valve dysfunction and failure (including valve leaflet thickening and thrombosis). A more granular 5-class

Published
2021

32. Pulmonary Embolism Response Team utilization during the COVID-19 pandemic

Author

Finn, Matthew T, primary, Gogia, Shawn, additional, Ingrassia, Joseph J, additional, Cohen, Matthew, additional, Madhavan, Mahesh V, additional, Nabavi Nouri, Shayan, additional, Brailovsky, Yevgeniy, additional, Masoumi, Amir, additional, Fried, Justin A, additional, Uriel, Nir, additional, Agerstrand, Cara I, additional, Eisenberger, Andrew, additional, Einstein, Andrew J, additional, Brodie, Daniel, additional, B Rosenzweig, Erika, additional, Leon, Martin B, additional, Takeda, Koji, additional, Pucillo, Anthony, additional, Green, Philip, additional, Kirtane, Ajay J, additional, Parikh, Sahil A, additional, and Sethi, Sanjum S, additional

Published
2021
Full Text
View/download PDF

33. Low and elevated- B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry

Author

Chen, Shmuel, Pibarot, Philippe, Redfors, Björn, Clavel, Marie-Annick, O’Neill, Brian P., Elmariah, Sammy, Nazif, Tamim, Crowley, Aaron, Ben-Yehuda, Ori, Finn, Matthew T., Alu, Maria C., Vahl, Torsten P., Kodali, Susheel, Leon, Martin B., Lindman, Brian R., Chen, Shmuel, Pibarot, Philippe, Redfors, Björn, Clavel, Marie-Annick, O’Neill, Brian P., Elmariah, Sammy, Nazif, Tamim, Crowley, Aaron, Ben-Yehuda, Ori, Finn, Matthew T., Alu, Maria C., Vahl, Torsten P., Kodali, Susheel, Leon, Martin B., and Lindman, Brian R.

Abstract

Aims : B-type natriuretic peptide (BNP) is a cardiac neurohormone that is secreted in response to ventricular volume expansion and pressure overload. There are conflicting data regarding the association between BNP levels and outcomes after transcatheter aortic valve replacement (TAVR). We therefore sought to assess the association between baseline BNP and adverse outcomes in patients with symptomatic, severe aortic stenosis (AS), and left ventricular ejection fraction (LVEF) >_50%, undergoing TAVR in the PARTNER 2 Trial and Registry. Methods and results : A total of 1782 patients were included in the analysis, and BNP was evaluated both as a continuous log- transformed value and by a priori categories: low (<50 pg/mL), normal (>_50 and <100 pg/mL), moderately elevated (>_100 and <400 pg/mL), or markedly elevated (>_400 pg/mL). Clinical outcomes from discharge to 2 years were compared between patients according to their baseline BNP level, using Kaplan–Meier event rates and multivariable Cox proportional hazards regression models. After adjustment, spline curves revealed a non-linear association be- tween log-transformed BNP and all-cause and cardiovascular mortality in which both the lowest and highest values were associated with increased mortality. Two-year all-cause mortality rates for those with low (n = 86), normal (n = 202), moderately elevated (n = 885), and markedly elevated (n = 609) baseline BNP were 20.0%, 9.8%, 17.7%, and 26.1%, respectively. In adjusted models, compared to a normal baseline BNP, low [adjusted hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.3–5.0, P-value 0.005], moderately elevated (adjusted HR 1.6, 95% CI 1.0–2.6, P-value 0.06), and markedly elevated (adjusted HR 2.1, 95% CI 1.3–3.5, P-value 0.003) BNP were associated with increased all-cause mortality, driven by cardiovascular mortality. Conclusions : In a large cohort of patients with severe symptomatic AS and preserved LVEF undergoing TAVR, all-cause and cardiovascular mortal

Published
2020

34. Contributors

Author

Ayatt, Youseff, Banerjee, Subhash, Basir, Mir Babar, Bitton-Faiwiszewski, Yonatan, Brilakis, Emmanouil S., Burke, M. Nicholas, Chatzizisis, Yiannis S., Drachman, Douglas E., Finn, Matthew T., Hall, Allison Barbara, Hawkins, Beau M., Helmy, Tarek, Kern, Morton J., Khan, Abdul Ahad, Klein, Andrew J.P., Kolte, Dhaval, Lemor, Alejandro, Lim, Michael J., Louvard, Yves R., Parikh, Sahil A., Reddy, H. Kiran Kumar, Sardar, Partha, Sethi, Sanjum S., Seto, Arnold H., Shroff, Adhir, Sorajja, Paul, Tafur, Jose D., Toole, Megan, and White, Christopher J.

Published
2023
Full Text
View/download PDF

39. Low and elevated- B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry

Author

Chen, Shmuel, Redfors, Björn, O’Neill, Brian P., Clavel, Marie-Annick, Pibarot, Philippe, Elmariah, Sammy, Nazif, Tamim, Crowley, Aaron, Ben-Yehuda, Ori, Finn, Matthew T., Alu, Maria C., Vahl, Torsten P., Kodali, Susheel, Leon, Martin B., Lindman, Brian R., Chen, Shmuel, Redfors, Björn, O’Neill, Brian P., Clavel, Marie-Annick, Pibarot, Philippe, Elmariah, Sammy, Nazif, Tamim, Crowley, Aaron, Ben-Yehuda, Ori, Finn, Matthew T., Alu, Maria C., Vahl, Torsten P., Kodali, Susheel, Leon, Martin B., and Lindman, Brian R.

Abstract

Aims : B-type natriuretic peptide (BNP) is a cardiac neurohormone that is secreted in response to ventricular volume expansion and pressure overload. There are conflicting data regarding the association between BNP levels and outcomes after transcatheter aortic valve replacement (TAVR). We therefore sought to assess the association between baseline BNP and adverse outcomes in patients with symptomatic, severe aortic stenosis (AS), and left ventricular ejection fraction (LVEF) >_50%, undergoing TAVR in the PARTNER 2 Trial and Registry. Methods and results : A total of 1782 patients were included in the analysis, and BNP was evaluated both as a continuous log- transformed value and by a priori categories: low (<50 pg/mL), normal (>_50 and <100 pg/mL), moderately elevated (>_100 and <400 pg/mL), or markedly elevated (>_400 pg/mL). Clinical outcomes from discharge to 2 years were compared between patients according to their baseline BNP level, using Kaplan–Meier event rates and multivariable Cox proportional hazards regression models. After adjustment, spline curves revealed a non-linear association be- tween log-transformed BNP and all-cause and cardiovascular mortality in which both the lowest and highest values were associated with increased mortality. Two-year all-cause mortality rates for those with low (n = 86), normal (n = 202), moderately elevated (n = 885), and markedly elevated (n = 609) baseline BNP were 20.0%, 9.8%, 17.7%, and 26.1%, respectively. In adjusted models, compared to a normal baseline BNP, low [adjusted hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.3–5.0, P-value 0.005], moderately elevated (adjusted HR 1.6, 95% CI 1.0–2.6, P-value 0.06), and markedly elevated (adjusted HR 2.1, 95% CI 1.3–3.5, P-value 0.003) BNP were associated with increased all-cause mortality, driven by cardiovascular mortality. Conclusions : In a large cohort of patients with severe symptomatic AS and preserved LVEF undergoing TAVR, all-cause and cardiovascular mortal

Published
2019

41. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry

Author

Chen, Shmuel, primary, Redfors, Bjorn, additional, O’Neill, Brian P, additional, Clavel, Marie-Annick, additional, Pibarot, Philippe, additional, Elmariah, Sammy, additional, Nazif, Tamim, additional, Crowley, Aaron, additional, Ben-Yehuda, Ori, additional, Finn, Matthew T, additional, Alu, Maria C, additional, Vahl, Torsten P, additional, Kodali, Susheel, additional, Leon, Martin B, additional, and Lindman, Brian R, additional

Published
2019
Full Text
View/download PDF

42. Impact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries

Author

Chen, Shmuel, primary, Redfors, Bjorn, additional, Nazif, Tamim, additional, Kirtane, Ajay, additional, Crowley, Aaron, additional, Ben-Yehuda, Ori, additional, Kapadia, Samir, additional, Finn, Matthew T, additional, Goel, Sachin, additional, Lindman, Brian R, additional, Alu, Maria C, additional, Chau, Katherine H, additional, Thourani, Vinod H, additional, Vahl, Torsten P, additional, Douglas, Pamela S, additional, Kodali, Susheel K, additional, and Leon, Martin B, additional

Published
2019
Full Text
View/download PDF

43. Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study

Author

Finn, Matthew T., primary, Redfors, Björn, additional, Karmpaliotis, Dimitri, additional, Kirtane, Ajay J., additional, Green, Philip, additional, McAndrew, Thomas, additional, Liu, Mengdan, additional, Cloney, Michael B., additional, Witzenbichler, Bernhard, additional, Weisz, Giora, additional, Stuckey, Thomas D., additional, Brodie, Bruce R., additional, Rinaldi, Michael J., additional, Neumann, Franz-Josef, additional, Metzger, D. Christopher, additional, Henry, Timothy D., additional, Cox, David A., additional, Duffy, Peter L., additional, Mazzaferri, Ernest L., additional, Mehran, Roxana, additional, and Stone, Gregg W., additional

Published
2019
Full Text
View/download PDF

45. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research.

Author

COMMITTEE, VARC-3 WRITING, Généreux, Philippe, Piazza, Nicolo, Alu, Maria C, Nazif, Tamim, Hahn, Rebecca T, Pibarot, Philippe, Bax, Jeroen J, Leipsic, Jonathon A, Blanke, Philipp, Blackstone, Eugene H, Finn, Matthew T, Kapadia, Samir, Linke, Axel, Mack, Michael J, Makkar, Raj, Mehran, Roxana, Popma, Jeffrey J, Reardon, Michael, and Rodes-Cabau, Josep

Subjects
AORTIC valve, MEDICAL research, CLINICAL trials, AORTIC valve insufficiency
Abstract

Aims  The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these endpoints for transcatheter and surgical aortic valve clinical trials. Rapid evolution of the field, including the emergence of new complications, expanding clinical indications, and novel therapy strategies have mandated further refinement and expansion of these definitions to ensure clinical relevance. This document provides an update of the most appropriate clinical endpoint definitions to be used in the conduct of transcatheter and surgical aortic valve clinical research. Methods and results  Several years after the publication of the VARC-2 manuscript, an in-person meeting was held involving over 50 independent clinical experts representing several professional societies, academic research organizations, the US Food and Drug Administration (FDA), and industry representatives to (i) evaluate utilization of VARC endpoint definitions in clinical research, (ii) discuss the scope of this focused update, and (iii) review and revise specific clinical endpoint definitions. A writing committee of independent experts was convened and subsequently met to further address outstanding issues. There were ongoing discussions with FDA and many experts to develop a new classification schema for bioprosthetic valve dysfunction and failure. Overall, this multi-disciplinary process has resulted in important recommendations for data reporting, clinical research methods, and updated endpoint definitions. New definitions or modifications of existing definitions are being proposed for repeat hospitalizations, access site-related complications, bleeding events, conduction disturbances, cardiac structural complications, and bioprosthetic valve dysfunction and failure (including valve leaflet thickening and thrombosis). A more granular 5-class grading scheme for paravalvular regurgitation (PVR) is being proposed to help refine the assessment of PVR. Finally, more specific recommendations on quality-of-life assessments have been included, which have been targeted to specific clinical study designs. Conclusions  Acknowledging the dynamic and evolving nature of less-invasive aortic valve therapies, further refinements of clinical research processes are required. The adoption of these updated and newly proposed VARC-3 endpoints and definitions will ensure homogenous event reporting, accurate adjudication, and appropriate comparisons of clinical research studies involving devices and new therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Impact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries.

Author

Chen, Shmuel, Redfors, Bjorn, Nazif, Tamim, Kirtane, Ajay, Crowley, Aaron, Ben-Yehuda, Ori, Kapadia, Samir, Finn, Matthew T, Goel, Sachin, Lindman, Brian R, Alu, Maria C, Chau, Katherine H, Thourani, Vinod H, Vahl, Torsten P, Douglas, Pamela S, Kodali, Susheel K, and Leon, Martin B

Abstract

Aims Left ventricular pressure overload is associated with activation of the cardiac renin–angiotensin system, which may contribute to myocardial fibrosis and worse clinical outcomes. We sought to assess the association between treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) at baseline and clinical outcomes in patients with symptomatic, severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) in the PARTNER 2 trial and registries. Methods and results A total of 3979 intermediate, high, or prohibitive risk patients who underwent TAVR in the PARTNER 2 trial and registries (excluding the valve in valve registry) were included in the study. Clinical outcomes at 2 years were compared according to baseline ACEI/ARB treatment status using Kaplan–Meier event rates and study-stratified multivariable Cox proportional hazards regression models. Sensitivity analysis was conducted using propensity score matching. Of 3979 patients who were included in the current analysis, 1736 (43.6%) were treated and 2243 (56.4%) were not treated with ACEI/ARB at baseline. Treatment with ACEI/ARB was associated with lower 2-year all-cause mortality (18.6% vs. 27.5%, P  < 0.0001), cardiovascular mortality (12.3% vs. 17.9%, P  < 0.0001), and non-cardiovascular mortality (7.2% vs. 11.7%, P  < 0.0001). Angiotensin-converting enzyme inhibitor/ARB treatment at baseline remained independently associated with a lower hazard of 2-year all-cause and cardiovascular mortality after multivariable adjustment, and propensity score matching. Conclusion In a large cohort of patients with severe symptomatic AS from the PARTNER 2 trial and registries, ACEI/ARB treatment at baseline was independently associated with a lower risk of 2-year all-cause and cardiovascular mortality. Open in new tab Download slide Open in new tab Download slide [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Intravascular ultrasound analysis of intraplaque versus subintimal tracking in percutaneous intervention for coronary chronic total occlusions: One year outcomes

Author

Finn, Matthew T., primary, Doshi, Darshan, additional, Cleman, Jacob, additional, Song, Lei, additional, Maehara, Akiko, additional, Hatem, Raja, additional, Redfors, Björn, additional, Kalra, Sanjog, additional, Fried, Justin A., additional, Liao, Ming, additional, Batres, Candido, additional, Moses, Jeffery W., additional, Parikh, Manish A., additional, Collins, Michael B., additional, Nazif, Tamim M., additional, Fall, Khady N., additional, Green, Phillip, additional, Kirtane, Ajay J., additional, Ali, Ziad A., additional, Leon, Martin B., additional, Mintz, Gary S., additional, and Karmpaliotis, Dimitri, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results